|
DOV Pharmaceutical, was a biotechnology company that focused on therapies primarily for central nervous system conditions. It was founded in 1995 by former employees of American Cyanamid (which was acquired by Wyeth in 1994), and in 1998 it in-licensed drugs discovered at American Cyanamid for further development.〔Neubauer, DN. "Indiplon". pp 453-464 in GABA and Sleep: Molecular, Functional and Clinical Aspects. Eds Jaime M. Monti, Seithikurippu Ratnas Pandi-Perumal, Hanns Möhler. Springer Science & Business Media, 2010 ISBN 9783034602266〕 It held an IPO on NASDQ in 2002,〔Edgar Online. (IPO Deal Data ) Page accessed July 15, 2015〕 and its shares plunged days later after negative details about a past relationship between Élan and DOV emerged.〔Hess, Diane, (Drugmaker's IPO Is a Big Headache ), TheStreet.com, 1 May 2002. Retrieved 5 November 2007. *Simpson, Stephen D. (A Pain DOV Pharmaceutical Couldn't Cure ), Motley Fool, 26 April 2006. Retrieved 5 November 2007.〕〔Krauskopf, Lewis, (Investors Suing Hackensack, N.J.-Based DOV Pharmaceutical over Stock Losses ), The Record (Hackensack, New Jersey), 2 May 2002. Retrieved 5 November 2007〕〔Maeillo, Michael, (The Coldest IPO... ), Forbes.com, 2 September 2002. Retrieved 5 November 2007〕〔(DOV IPO sinks on first day ), CNN.com, 25 April, 2002. Retrieved 5 November 2007〕 After several failed clinical trials, in 2010 Dov was acquired by Euthymics Bioscience which intended to continue development of Dov's antidepressant, DOV 21,947 (renamed EB-1010).〔Fierce Biotech July 22, 2010 (Euthymics lands $24M to fund antidepressant work )〕 Its drug candidates included: * Indiplon for insomnia, licensed from Wyeth in 1998, which it licensed to Neurocrine Biosciences in 1998.〔 * Bicifadine, a triple-uptake inhibitor for pain, licensed from Wyeth in 1998,〔 * Triple-uptake inhibitors for depression and related psychiatric disorders: (DOV 21,947 and DOV 216,303) licensed from Wyeth in 1998.〔Marks DM, Pae CU, Patkar AA. Triple reuptake inhibitors: a premise and promise. Psychiatry Investig. 2008 Sep;5(3):142-7. PMID 20046357 (PMC2796030 )〕 Merck sublicensed the rights in 2004,〔Chemical and Engineering News. August 12, 2004 (Merck and DOV Pharmaceutical In Drug Pact )〕 and terminated them in 2006.〔Dov December 8, 2006 (DOV Pharmaceutical Announces Termination Of License Agreement With Merck & Co., Inc. (MRK) )〕 * Ocinaplon for anxiety disorders.〔Edgar Online. Data as of May 2004 (IPO Deal Data: Business Description ) Page accessed July 15, 2015〕 * A proprietary formulation of diltiazem〔 * DOV 102,677, for the treatment of Parkinson's disease, restless leg syndrome, attention deficit disorder〔 * DOV 51,892, for anxiety disorders〔 ==References== 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「DOV Pharmaceutical」の詳細全文を読む スポンサード リンク
|